NEW YORK, Jan. 31 - A Decode subsidiary will collect and analyze pharmacogenomics data for a clinical study performed by Vertex Pharmaceuticals.
The agreement with the unit, Encode, aims at providing Vertex with pharmacogenomics data on therapeutics responses in patients treated with Vertex drug candidate for psoriasis, the companies said.
The deal also may lead the partners to design pharmacogenomics tests, in which event the companies would develop and commercialize.
Click here for more information.